Correlation Between Cardiac Markers and Severity of COVID-19

Completed

• Conditions: Cardiac Event
• Interventions: Other: laboratory investigation

• Registration Number: NCT05040750
• Lead Sponsor: Ain Shams University

Brief Summary

By July 9, 2020, the global pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection had resulted in over 11.8 million confirmed cases and over 545000 deaths. Patients with a history of cardiovascular disease are especially vulnerable and have a bad prognosis. According to the findings, cardiac injury manifested by cardiac biomarker elevation is detected in a significant number of COVID-19 patients and is linked to poor outcomes and mortality. However, it is unclear how effective cardiac biomarkers are in COVID-19 prognosis and how to use these indicators.

Detailed Description

The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection has led to \>11.8 million confirmed cases with \>545000 deaths worldwide by July 9, 2020 Patients with preexisting cardiovascular conditions are particularly at risk and have poor prognosis data suggest that cardiac injury, manifested by cardiac biomarker elevation, is detected in a sizable of COVID-19 patients and is associated with adverse outcomes and increased mortality. However, how useful cardiac biomarkers are in COVID-19 prognosis and how to utilize these markers have not been well defined The study will include all moderate to severe COVID 19 patients admitted to ICU. Both genders within the age group 18-60 years were included. The primary outcome is the relation between cardiac markers and mortality rate in critically ill COVID 19 patients The secondary outcome is the relationship between cardiac and inflammatory and coagulation markers

Study Timeline

• Study Start: 2021-09-01
• Study First Submitted: 2021-09-09
• Study First Submitted QC: 2021-09-09
• Study First Posted: 2021-09-10
• Primary Completion: 2023-07-30
• Study Completion: 2023-07-30
• Status Verified: 2024-10
• Last Update Submitted: 2024-10-07
• Last Update Posted: 2024-10-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 207

Inclusion Criteria

• all moderate to severe COVID 19 patients who were admitted to ICU.
• Both genders
• age group 18-60 years

Read More

Exclusion Criteria

• a refusal to participate in the study,
• pregnant patients,
• patients aged <18 or >60. years,
• recent history of acute myocardial infarction (< 1 month before admission).

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
moderate to severe COVID 19 patients	laboratory investigation	moderate to severe COVID 19 patients admitted to ICU. Both genders within the age group 18-60 years were included. Diagnosis of COVID 19 was confirmed

Primary Outcome Measures

Name	Time	Method
relation between cardiac markers and mortality rate in critically ill COVID 19 patients	4 month	relate cardiac biomarkers to mortality rate

Secondary Outcome Measures

Name	Time	Method
relation ship between cardiac and inflammatory and coagulation markers	4 month	compare cardiac markers to inflammatory and coagulation laboratory findings

Trial Locations

Locations (1)

Ain Shams University; 🇪🇬 Cairo, Egypt